Medicare Enrolled

Dr. Alexander Perl, MD

Medical Oncology · Philadelphia, PA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Consulting-driven
3400 SPRUCE ST, Philadelphia, PA 19104
2156623914
In practice since 2006 (20 years)
NPI: 1801824321 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Perl from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Perl? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Perl

Dr. Alexander Perl is a medical oncology specialist in Philadelphia, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Perl performed 376 Medicare services across 163 unique beneficiaries.

Between the years covered by Open Payments, Dr. Perl received a total of $168,271 from 21 pharmaceutical and/or device companies across 173 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Perl is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ 376 Medicare services $168,271 industry payments

Medicare Practice Summary

Medicare Utilization ↗
376
Medicare services
Bottom 44% in PA for medical oncology
163
Unique beneficiaries
$96
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~19 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
112 $99 $292
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
94 $66 $208
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
91 $119 $266
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
50 $78 $167
New patient office visit, complex (60-74 min) 17 $142 $430
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
12 $144 $586
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$168,271
Total received (2018-2024)
Avg $24,039/year across 7 years
Top 5% in PA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
21
Companies
173
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$114,712 (68.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$40,095 (23.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$13,463 (8.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$7,499
2023
$22,059
2022
$8,308
2021
$5,508
2020
$25,985
2019
$66,497
2018
$32,415

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Astellas Pharma US Inc
$3,949
Daiichi Sankyo Inc.
$3,448
ABBVIE INC.
$52
Genentech USA, Inc.
$51
Top 3 companies account for 99.3% of 2024 payments
All-time payments by company (2018-2024) ›
Daiichi Sankyo Inc.
$36,376
Astellas Pharma Global Development
$28,871
Astellas Pharma US Inc
$15,296
AbbVie, Inc.
$13,998
Astellas Pharma Inc
$13,587
Jazz Pharmaceuticals Inc.
$12,920
AbbVie Inc.
$11,347
Daiichi Sankyo Company LTD
$8,499
Takeda Pharmaceuticals U.S.A., Inc.
$8,430
Agios Pharmaceuticals, Inc.
$5,927
Celgene Corporation
$4,638
Genentech USA, Inc.
$2,134
ABBVIE INC.
$1,961
Genentech, Inc.
$1,953
Eli Lilly Export S.A. Puerto Rico Branch
$1,050
Amgen Inc.
$806
Gilead Sciences, Inc.
$166
JAZZ PHARMACEUTICALS INC.
$130
Novartis Pharmaceuticals Corporation
$111
Eli Lilly and Company
$46
Janssen Scientific Affairs, LLC
$24
Top 3 companies account for 47.9% of all-time payments
Associated products mentioned in payments ›
DEFITELIO · IMBRUVICA · KYMRIAH · ONUREG · RYLAZE · TIBSOVO · VENCLEXTA · VYXEOS · Vanflyta · Venclexta · XOSPATA · Xospata
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (68%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 5% for medical oncology in PA.

Looking for a medical oncology specialist in Philadelphia?
Compare medical oncologists in the Philadelphia area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists within 10 mi
118
Per 100K population
7.5
County median income
$60,698
Nearest hospital
PHILADELPHIA VA MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Perl is a clinical cardiology specialist, with moderate Medicare volume, with consulting-driven industry engagement in the top 5% of PA peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Perl experienced with hospital follow-up visit, high complexity?
Based on Medicare claims data, Dr. Perl performed 112 hospital follow-up visit, high complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Perl receive payments from pharmaceutical companies?
Yes. Dr. Perl received a total of $168,271 from 21 companies across 173 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Perl's costs compare to other medical oncologists in Philadelphia?
Dr. Perl's average Medicare payment per service is $96. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Perl) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →